MRNS - Marinus Pharmaceuticals, Inc. Net Sales Margin

MRNS (Marinus Pharmaceuticals, Inc.) - company brandmark

Geopolitical risks and raw material supply disruptions are weighing on Marinus Pharmaceuticals (MRNS), as evidenced by the volatility on the net profitability chart. Niche leadership in epilepsy therapy across various age groups stabilizes the business, yet the failure of final drug tests is forcing the company to cut costs. The current -446.50 figure reflects the state of the sales margin metric amid the search for strategic partners.

Marinus Pharmaceuticals (MRNS) Net Profit Rate: for the period 07/04/2022 - 02/22/2025

MRNS (Marinus): analytical breakdowns and indicator data

Basic company analysis:Marinus Pharma - MRNS
Flagship merchandise of Marinus Pharmaceuticals Inc

The commercialization of Ztalmy and expansion into the rare epilepsy segment drive the current operational efficiency of Marinus Pharmaceuticals (MRNS). This indicator is calculated as the ratio of net income to revenue, measuring the portion of every dollar of income remaining after all expenses. Analyzing the net profit margin allows for the identification of hidden costs prior to official reports. This trend captures the resilience of the business model as the drug scales. Stable margin growth signals to the market that the invested capital is protected.

Analysis of competing companies

BIIB: Net Sales Margin|Net Margin Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Corp) - Net Sales Margin|AXSM: Net Profit Rate|Net Margin acadia-pharm.com (ACAD)|Net Sales Margin Xenon Pharmaceuticals (XENE)|Net Margin Viking Therapeutics VKTX|Net Profit Rate SUPN|CPRX - Net Margin|Net Margin Denali Therapeutics|HRMY: Net Sales Margin|Biohaven - Net Profit Rate|Return on Sales by Net Profit AMLX|Trevi Therapeutics, Inc. (TRVI) - Company Sales Margin|Return on Sales by Net Profit PRAX (Praxis Medicines)|Anavex Corp - Net Return on Sales|Net Margin CeriBell CBLL|Company Sales Margin Prothena Biosciences (PRTA)|ALEC: Return on Sales by Net Profit|ANNX - Net Sales Margin|Omeros Corp. (OMER) - Net Margin|Net Margin Neurogene Inc. (NGNE)|Return on Sales by Net Profit ACIU|Net Margin VYGR|Net Margin Neumora (NMRA)|SCLX - Net Margin|Net Sales Margin TVGN (Tevogen Bio Holdings Inc.)|Net Profit Rate ACOG|Cognition Therapeutics Inc. - Net Sales Margin|IKT - Net Sales Margin|SAVA: Net Sales Margin|Assertio Holdings, Inc. - Net Profit Rate|COYA (Coya) - Net Sales Margin|Net Return on Sales VTGN (Vistagen Therapeutics)|Net Margin Ovid Rx (OVID)|Acumen Pharmaceuticals - Net Return on Sales|Net Margin CervoMed, Inc. CRVO|Net Sales Margin Alterity Therapeutics ATHE|CLNN: Return on Sales by Net Profit|PEPG (pepgen.com) - Net Return on Sales|Jupiter Neurosciences Inc (JUNS) - Net Margin|Relmada Therapeutics - Net Profit Rate|ANVS (Annovis Bio Inc) - Net Sales Margin|GRCE: Net Profit Rate|Net Margin Firefly Neuroscience Inc (AIFF)|KLTO (ANEW Medical) - Net Profit Rate|Net Margin neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Net Margin|MTVA: Return on Sales by Net Profit|NeurAxis, Inc (NRXS) - Return on Sales by Net Profit|HSDT: Net Sales Margin|PASG - Company Sales Margin|Net Margin Neuphoria Therapeutics, Inc.|Net Margin NERV|Net Sales Margin ATHA|ADXN (Addex Therapeutics Ltd) - Net Profit Rate|Net Margin alzamend.com ALZN|Company Sales Margin Cyclerion Therapeutics (CYCN)|Protagenic - Net Sales Margin|Net Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Net Sales Margin|Avenue Therapeutics Inc. (ATXI) - Net Sales Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Net Sales Margin|Net Sales Margin Cara Therapeutics Inc|Net Margin Chromocell Therapeutics (CHRO)|Company Net Profitability ELYM|Net Margin Intra-Cellular ITCI|LBPH: Net Return on Sales|NKGen Biotech Corp - Net Sales Margin|Net Profit Rate NRBO (NeuroBo Pharma)|SAGE (Sage Therapeutics, Inc) - Return on Sales by Net Profit|Net Return on Sales SNPX|Return on Sales by Net Profit TRVN|Net Margin VIGL|Net Sales Margin WENA|Company Sales Margin Cerevel